ArticleJournal of clinical microbiology2026
Diagnostic value of HHV-6A/B genotyping in immunocompromised adults.
Article in Journal of clinical microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Human herpesvirus 6 (HHV-6) comprises two genetically and biologically distinct species, HHV-6A and HHV-6B, yet species-level differentiation is rarely performed in clinical practice. We conducted a retrospective study of 119 immunocompromised adults with detectable HHV-6 DNA between 2020 and 2025 to characterize species distribution, compare epidemiological, clinical, and virological features, and evaluate the diagnostic relevance of genotyping. Viral species were detected by real-time polymerase chain reaction (PCR) across multiple sample types, and suspected chromosomal integration was confirmed through detection of endogenous HHV-6 (eHHV-6) DNA in hair follicles by quantitative real-time PCR. HHV-6B accounted for ~96% of infections and was significantly associated with organ involvement, predominantly gastrointestinal disease, irrespective of plasma viral load. In contrast, HHV-6A was less frequently detected in tissues and was consistently associated with viremia and chromosomal integration, independent of viral load. Genotypic concordance across plasma, biopsy, cerebrospinal fluid, bronchoalveolar lavage, and hair follicle samples from the same patient was complete. Incorporating species-level genotyping and targeted testing for chromosomal integration (eHHV-6) into diagnostic workflows may improve interpretation of viral detection and help prevent unnecessary antiviral therapy.IMPORTANCESpecies-specific identification of human herpesvirus 6 (HHV-6A/B) has critical diagnostic implications in immunocompromised patients, although it is rarely performed in diagnostic laboratories. Our study showed that HHV-6A detection is associated with chromosomal integration, whereas HHV-6B is the main species linked to clinically relevant disease and invasive tissue infection. This study emphasizes that implementing species-specific PCR and testing for eHHV-6 in clinical microbiology laboratories may help interpret viral DNA detection, prevent misclassification of integrated virus as active infection, and avoid unnecessary antiviral therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.